Data Sheet (Cat.No.TMPK-00752)

TargetMol

LY6G6D Protein, Human, Recombinant (hFc)

General Information

Synonyms:	G6D;MEGT1;C6orf23;NG25;Protein Ly6-D;Ly6-D
Protein Construction:	Asn20-Ser104
Species:	Human
Expression Host:	HEK293 Cells
Accession:	O95868
Molecular Weight:	35.87 kDa (predicted). Due to glycosylation, the protein migrates to 40-50 kDa based on Tris-Bis PAGE result.

QC Testing

Biological Activity:	Immobilized Human LY6G6D, hFc Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Anti-LY6G6D Antibody, hFc Tag with the EC50 of 14.6ng/ml determined by ELISA.
Purity:	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
Endotoxin:	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation:	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization.

Preparation and Storage

Reconstitution:

Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.

Stability & Storage:

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

Shipping:

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

Protein Background

LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager.LY6G6D was identified as a selectively expressed CRC antigen that can be utilized to potently re-direct and activate cytotoxic T-cells to lyse LY6G6D expressing CRC using a TcE. This effect can be spread to target negative neighboring tumor cells, potentially leading to improved therapeutic efficacy.

Reference

Corrales L, et al. LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager. Front Immunol. 2022 Sep 8;13:1008764. doi: 10.3389/fimmu.2022.1008764. PMID: 36159851; PMCID: PMC9493073.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481